|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Decreased activity of CUGBP2 could be associated with high chemoresistance and early dissemination of pancreatic cancer through the HO-1- and COX-2-mediated cytoprotective and carcinogenesis pathways.
|
26691217 |
2016 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Studies of the molecular pathology of pancreatic cancer have revealed that activation of KRAS, overexpression of cyclooxygenase-2, inactivation of p16(INK4A) and loss of p53 activities occurred in pancreatic cancer.
|
25152585 |
2014 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
CTD_human |
COX-2 activity was significantly elevated in hamster and human pancreatic cancers compared to pair-matched normal pancreas.
|
16820089 |
2006 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
CTD_human |
The aim of the present study was to evaluate the effect of selective COX-2 inhibitors on vascular endothelial growth factor (VEGF) production in vitro and angiogenesis and growth of pancreatic cancer in vivo, focusing on putative differences between COX-2-negative and COX-2-positive tumors.
|
15705899 |
2005 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we report that apricoxib, a novel COX-2 inhibitor in phase II clinical trials, significantly enhances the efficacy of gemcitabine/erlotinib in preclinical models of pancreatic cancer.
|
22829202 |
2012 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the role of COX-2 in pancreatic cancer, we evaluated COX-2 protein expression in primary human pancreatic adenocarcinomas (n = 23) and matched normal adjacent tissue (n = 11) by immunoblot analysis.
|
10657949 |
2000 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, indomethacin and NS398 were equipotent for growth inhibition and induction of apoptosis, indicating that eicosanoid synthesis via COX-2 is involved in pancreatic cancer cell proliferation and survival.
|
10953335 |
2000 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
HMGA1 binds directly to the COX-2 promoter at an AT-rich region in vivo in three pancreatic cancer cell lines.
|
22898640 |
2013 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that COX-2-765*C is related to cancer susceptibility and may increase gastric and pancreatic cancer risk.
|
24969885 |
2014 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray.
|
16481301 |
2006 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These preliminary results indicate that the -1195G/A COX-2 polymorphism may play an important role in PC prognosis and carcinogenesis.
|
22039326 |
2011 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both the insulin-like growth factor-I receptor (IGF-IR) and cyclooxygenase-2 (COX-2) are frequently overexpressed in pancreatic cancer.
|
17950526 |
2007 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we tested the hypothesis that the COX-2 product prostaglandin E(2) (PGE(2)) increases cellular invasive potential by inducing matrix metalloproteinase-2 (MMP-2) expression and activity through an extracellular signal-regulated kinase (ERK)/Ets-1-dependent mechanism in pancreatic cancer.
|
15492268 |
2004 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
|
16373709 |
2005 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
CTD_human |
To investigate the role of COX-2 in pancreatic cancer, we evaluated COX-2 protein expression in primary human pancreatic adenocarcinomas (n = 23) and matched normal adjacent tissue (n = 11) by immunoblot analysis.
|
10657949 |
2000 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined expression and epigenetic alterations of cyclooxygenase-1 (COX-1) and COX-2 in pancreatic cancers and normal pancreas and performed proliferation, knockdown, and coculture experiments to understand the role of stromal sources of prostaglandins for pancreatic cancers.
|
20530583 |
2010 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have developed a novel synthetic compound-CDF, which showed greater bioavailability in animal tissues such as pancreas, and also induced cell growth inhibition and apoptosis, which was mediated by inactivation of NF-κB, COX-2, and VEGF in pancreatic cancer (PC) cells.
|
21408027 |
2011 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prostaglandin-endoperoxide synthase 2 (COX-2) is considered a therapeutic target for prevention of pancreatic cancer.
|
29896263 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study adds additional evidence that the COX-2 pathway is involved in pancreatic carcinogenesis and suggests that urinary PGE-M may serve as a biomarker for predicting pancreatic cancer risk.
|
28815606 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our findings indicate that COX-2 up-regulation is a frequent event in pancreatic cancers and suggest that nonsteroidal anti-inflammatory drugs may be useful in the chemoprevention and therapy of pancreatic carcinoma.
|
10485483 |
1999 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Several studies have described an increased cyclooxygenase-2 (COX-2) expression in pancreatic cancer, but the role of COX-2 in tumour development and progression is not clear.
|
24912820 |
2014 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate a possible link between bile acids and the pathogenesis of pancreatic cancer, we determined whether conjugated or unconjugated bile acids induced cyclooxygenase-2 (COX-2) in two human pancreatic cancer cell lines, BxPC-3 and SU 86.86.
|
14656949 |
2004 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of COX-2 may represent an intriguing strategy to prevent pancreatic cancer in high-risk patients.
|
17652141 |
2007 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Significant inhibition of VEGF, angiopoietin 1, angiopoietin 2, platelet derived growth factor, COX-2, and TGFβ secretion was observed in PC cell lines treated with UBS109, EF31 or curcumin.
|
25497868 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study examined the functional relevance of genetic polymorphisms in the COX-2 promoter and evaluated their associations with susceptibility to pancreatic cancer.
|
19422084 |
2009 |